Login to Your Account

Pharma: Other News To Note

Friday, March 15, 2013
• Astellas Pharma Inc., of Tokyo, said the European Commission approved expanded options for pre-treatment prior to use of Qutenza (8 percent capsaicin patch). Before application, the patient may now take an oral analgesic, or the treatment area may be pre-treated with a topical anesthetic.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription